Clinical trial Recruiting at 3 sites Interventional Ages Any age to 7 Days

Improving outcomes for infants exposed to cannabinoids during pregnancy

Official title: Pilot Feasibility Trial of Improving Neurodevelopmental ouTcomes After Prenatal Cannabinoid in uTero Exposure (INTACT)

Run by IDeA States Pediatric Clinical Trials Network · NCT06423664 · Data updated 2026-11-12

This study is trying out a coaching program for parents to see if it helps improve the development of infants who were exposed to cannabinoids before birth.

Quick facts

Study typeInterventional
AgesAny age to 7 Days
SexAll
Enrollment20 (estimated)
SponsorIDeA States Pediatric Clinical Trials Network
Research network
Locations3 sites (Albuquerque, New Mexico and 2 other locations)
StatusRecruiting
StartedFebruary 6, 2025
Main results expectedJune 10, 2026
Study endsAugust 31, 2026
Registry record updatedJune 24, 2025
Trial IDNCT06423664 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include birthing parents who used cannabinoids during pregnancy and have a singleton live birth infant who is at least 37 weeks gestation.

Probably not a fit

Patients who used other illicit drugs or opiates during pregnancy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The INTACT trial is a multisite pilot feasibility study aimed at evaluating the effectiveness of the INTACT Intervention program in enhancing neurodevelopmental outcomes in infants who were prenatally exposed to cannabinoids. This study will enroll 20 birthing parent/infant dyads across three sites and will focus on the feasibility of the intervention rather than clinical outcomes. The intervention consists of 12 monthly coaching sessions that train birthing parents in effective parenting practices and contingent responding techniques to support their infants' early development. The study will assess participant recruitment, completion, and adherence over a duration of 22 months.

Why it matters

Potential benefit: If successful, this intervention could significantly improve early language, cognitive, and social development in infants exposed to cannabinoids in utero.

How similar studies have gone: While this approach is novel in its specific focus on cannabinoid exposure, similar interventions targeting developmental outcomes in at-risk populations have shown promise in other studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Birthing Parent

* Age of majority, as defined by the state of residency
* Cannabinoid use during pregnancy confirmed with self-report
* Have the ability to speak, read, and understand English
* Birthing parent who delivered at one of the hospitals where study team members have clinical privileges to access medical records
* Has parental custody of the infant
* Singleton pregnancy with live birth
* Has an electronic device capable of watching videos and able to stream/download videos for viewing and permitting video conferencing
* Has study access to the internet

Infant

* Term infants at birth (\>37 weeks' gestation)
* Biological child of the birthing parent

Exclusion Criteria:

Birthing Parent

* Other illicit drug use, excluding cannabinoids, during pregnancy (such as heroin or cocaine) per self-reported or toxicology results
* Opiate use (prescribed or unprescribed) per self-report or toxicology results during this pregnancy
* Prolonged hospitalization following delivery longer than 7 days

Infant

* Has major birth defect(s) including physical anomalies including limb malformations/absence of limbs or chromosomal abnormalities
* Diagnosed with neonatal encephalopathy, metabolic disorder, stroke, intracranial hemorrhage, or meningitis during birth hospitalization
* Received any major surgical intervention during the birth hospitalization or required a prolonged birth hospitalization (prolonged hospitalization being any hospitalization longer than 7 days)

Where it's running

  • University of New Mexico Health Sciences Center
    Albuquerque, New Mexico, United States
    Recruiting
  • Avera Research Institute
    Sioux Falls, South Dakota, United States
    Recruiting
  • University of Vermont Medical Center
    Burlington, Vermont, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.